Prognostic model for survival in patients with metastatic renal cell carcinoma: results from the international kidney cancer working group.
about
Cytoreductive nephrectomy and its role in the present-day period of targeted therapy.Metastatic renal cell carcinoma: update on epidemiology, genetics, and therapeutic modalitiesCirculating biomarkers in advanced renal cell carcinoma: clinical applicationsRenal cell cancer: overview of the current therapeutic landscape.Modeling the overall survival of patients with advanced-stage non-small cell lung cancer using data of routine laboratory tests.A five-factor biomarker profile obtained week 4-12 of treatment for improved prognostication in metastatic renal cell carcinoma: Results from DARENCA study 2.Tumoral cubilin is a predictive marker for treatment of renal cancer patients with sunitinib and sorafenibAssociation of post-treatment hypoalbuminemia and survival in Chinese patients with metastatic renal cell carcinoma.External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based studyManagement of metastatic renal cell carcinoma patients with poor-risk features: current status and future perspectives.Prognostic factors for overall survival with targeted therapy in Chinese patients with metastatic renal cell carcinoma.Microvessel area as a predictor of sorafenib response in metastatic renal cell carcinomaDisease-specific survival in de novo metastatic renal cell carcinoma in the cytokine and targeted therapy era.Tyrosine kinase inhibitors in the treatment of advanced renal cell carcinoma: focus on pazopanib.Prognosis of Japanese patients with previously untreated metastatic renal cell carcinoma in the era of molecular-targeted therapy.Prognostic factors for survival in patients with metastatic renal cell carcinoma treated with targeted therapies.Biomarkers for tyrosine kinase inhibitors in renal cell cancer.Therapeutic challenges in advanced renal cell carcinomaDevelopment and validation of a prognostic model in patients with metastatic renal cell carcinoma treated with sunitinib: a European collaboration.Conditional survival of metastatic renal cell carcinoma patients treated with high-dose interleukin-2.Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma.Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with pazopanib after disease progression with other targeted therapiesMetastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: characterization of survival outcome and application of the International mRCC Database Consortium criteria.A Three-Variable Model Predicts Short Survival in Patients With Newly Diagnosed Metastatic Renal Cell Carcinoma.Prognostic factors of overall survival in renal cancer patients - single oncological center study.The prognostic value of histological tumor necrosis in solid organ malignant disease: a systematic review.Targeted therapies in metastatic renal cell carcinoma: overview of the past year.Predictive models for the practical management of renal cell carcinoma.Treatment selection in metastatic renal cell carcinoma: expert consensus.Sequential therapy in metastatic clear cell renal carcinoma: TKI-TKI vs TKI-mTOR.Optimal management of metastatic renal cell carcinoma: current status.Prognostic biomarkers for patients with advanced renal cell carcinoma treated with VEGF-targeted tyrosine kinase inhibitors.Recommendations for the clinical and radiological evaluation of response to treatment in metastatic renal cell cancer.Management of metastatic kidney cancer in the era of personalized medicine.Prognostic factors in patients with advanced renal cell carcinoma treated with VEGF-targeted agents.Prognostic factors and risk classifications for patients with metastatic renal cell carcinoma.Does a reasonable treatment approach beyond second-line exist?Optimal treatment of poor-risk renal cell carcinoma patients with mTOR inhibitors and anti-VEGFR agents.Current Management Options in Metastatic Renal Cell Cancer.Targeted therapies in advanced renal cell carcinoma: the role of metastatic sites as a prognostic factor.
P2860
Q26783520-78D3BD1A-4AD8-4504-802C-702443A53374Q26852437-14A5BB97-AC19-4686-AD1B-5A7DF6B4EADBQ27023770-BAAED469-6155-4692-A6EE-7F905A91F187Q30248354-C3A4EDAB-3455-44F6-8F1C-E56EA4823338Q30827122-BC03B783-F60B-4CA6-A674-021EC9053732Q33426559-61E025E5-940C-43ED-8D8C-1415BC9EA3C4Q33665833-47EF4965-D42E-462C-8759-542F92917E78Q33702779-9867E4CD-D429-4FFD-B599-34E982050BF6Q34086969-5547F0F9-0355-47E2-B332-C27AECED675DQ34351372-549D116E-FEE8-4977-A330-30399375BF9DQ34602155-0A6D17C3-4FCD-4520-A2F4-E5D7D0BEAA9FQ34658963-20375D1C-F8B0-4B46-92F9-80248F57F1D7Q34713136-A69DB67A-3709-49BA-B0D1-D835F4D19F0AQ35534962-E8E1A9C4-D16D-41B7-8DCB-71C2FBFCCC04Q35674216-551D44CF-0834-4C36-8303-26E456DA8F66Q36387848-8AB5367C-5771-46AB-A746-9B8EF1DC34E5Q36450612-C819A732-5344-41AD-8A99-0FF04B2AA5AEQ36573665-EFC16FA7-22C9-44C7-9042-74F2087581CAQ37040692-6822A833-CECD-4D38-B9BA-D32D6F01C8D8Q37301538-9CE10599-2589-4F87-B8D9-F72F63DA5D2FQ37414808-4C8DB14B-732A-45C3-B339-58BDEA9263BDQ37438970-D0A8B480-F1DF-4B82-A624-E8F3A968CE8FQ37602903-1EE2ECC8-CA6D-4D67-B61B-445CDAE3D4BFQ37672155-F7044F2F-9D47-40DC-BE86-2B10660696EAQ37682403-02A90680-FFA9-4295-92E2-37270DD556C7Q37944938-F0645278-882D-4B9C-9560-738AA30E4B68Q37964565-CEAB435D-67EB-48F1-A33C-802C710A927CQ37974504-E217CE51-8900-448D-A921-F4C845C35037Q37999655-B15BCB30-4C79-4D76-8269-D3313D81E45CQ38068584-65878DB3-85D1-4172-BAE2-E73411D01ACBQ38097746-910653CA-838D-4AE4-AAFC-0E31B44876F7Q38116001-29ADEBDF-8723-43C2-AB3D-58A65E52A546Q38171376-45177AA5-33BA-4E4E-9EE3-580AF7C424B5Q38180744-A1ADFFA5-00E2-43DC-96C8-C416CAB96AA0Q38196855-C7C60A17-420B-4200-BA6F-CA638A01E612Q38543085-FD41F9E1-A27E-4954-BB31-0C0DE18028E0Q38555875-DE50DA9F-993E-4989-A5F2-619E0924176CQ38624864-C611311E-DB24-454D-8CD2-53D6B856BA16Q38662325-C8755E17-0761-4CDF-8349-61DE0D49E16AQ39155548-1068FE5D-28D3-4ABC-B477-A5DBFC259B02
P2860
Prognostic model for survival in patients with metastatic renal cell carcinoma: results from the international kidney cancer working group.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Prognostic model for survival ...... l kidney cancer working group.
@ast
Prognostic model for survival ...... l kidney cancer working group.
@en
type
label
Prognostic model for survival ...... l kidney cancer working group.
@ast
Prognostic model for survival ...... l kidney cancer working group.
@en
prefLabel
Prognostic model for survival ...... l kidney cancer working group.
@ast
Prognostic model for survival ...... l kidney cancer working group.
@en
P2093
P2860
P50
P1476
Prognostic model for survival ...... l kidney cancer working group.
@en
P2093
Daniel Y C Heng
International Kidney Cancer Working Group
Janice Dutcher
Jennifer Bacik McCormack
Judith Manola
Madhu Mazumdar
Michael Atkins
Paul Elson
Ronald Bukowski
Sylvie Négrier
P2860
P304
P356
10.1158/1078-0432.CCR-11-0553
P407
P577
2011-08-09T00:00:00Z